Auvelity (dextromethorphan-bupropion): state of practice

Mechanism: why the two drugs are combined

Dextromethorphan is a low-affinity NMDA receptor antagonist and a sigma-1 receptor agonist. It's the same molecule found in cough syrup, which is not incidental. At normal cough-suppressant doses, dextromethorphan has modest antidepressant-relevant activity, but it's metabolized so quickly by CYP2D6 (to dextrorphan, then further glucuronidated) that reaching therapeutic brain levels for depression is hard.

Bupropion is a moderate CYP2D6 inhibitor. Adding bupropion slows dextromethorphan clearance enough that a standard oral dose reaches plasma levels closer to what an IV or intranasal ketamine dose achieves in terms of NMDA effect. The bupropion in Auvelity is doing pharmacokinetic work as much as pharmacodynamic work. It contributes its own monoaminergic mechanism (NDRI), so the drug is not purely an NMDA modulator, but the primary novelty is the dextromethorphan side.

Whether the mechanism actually explains the fast onset is a separate question. The GEMINI trial and the ASCEND phase 2 study both showed faster antidepressant separation than SSRIs, and the leading hypothesis is that NMDA modulation acts more directly on downstream mood circuits (glutamate, BDNF, synaptic plasticity) than monoamine reuptake inhibition does. This is the same theoretical family as ketamine.

What the trials showed

Two trials support the approval:

ASCEND (Tabuteau et al., Am J Psychiatry 2022) was the Phase 2 trial. It compared dextromethorphan-bupropion to bupropion alone, testing whether the combination outperformed the CYP2D6 inhibitor by itself. It did. HAM-D-17 separation from bupropion was around 3 to 4 points at week 6, with earlier separation than either arm produced alone.

GEMINI (Iosifescu et al., Am J Psychiatry 2022) was the pivotal Phase 3 trial. It compared dextromethorphan-bupropion to placebo in 327 adults with moderate to severe MDD. The MADRS separation from placebo was 3.9 points at week 6, with statistically significant separation as early as week 1. Response rates (50 percent MADRS reduction) at week 6 were 54 percent for the drug versus 34 percent for placebo. Remission rates were 40 percent versus 17 percent. The effect sizes are similar to SSRIs at week 6, but the onset kinetics look faster.

A criticism worth acknowledging: neither trial was compared to an active SSRI or SNRI control. The comparators were placebo (GEMINI) and bupropion monotherapy (ASCEND). So the claim of "faster onset than SSRIs" is inferential, not head-to-head. In practice, some patients respond in the first two weeks and some take the full six weeks, similar to any antidepressant.

Dosing

The regimen is dextromethorphan 45 mg / bupropion 105 mg once daily for three days, then twice daily thereafter. Maximum dose is two tablets twice daily (dextromethorphan 90 mg / bupropion 210 mg twice daily). The label allows a maximum of 190 mg bupropion equivalent per day for patients with moderate hepatic impairment.

The dosing is straightforward compared to most psychiatric medications: no titration to therapeutic dose beyond day 3, no weight-based adjustment, no need for TDM. That simplicity is worth something in real practice.

Missed doses: if a dose is missed, skip it and take the next scheduled dose. Do not double up. The bupropion component makes double dosing riskier for seizure than the dextromethorphan component makes it riskier for anything else.

CYP2D6 pharmacogenetics

This is the drug's most complicated interaction. Bupropion inhibits CYP2D6. Dextromethorphan is metabolized by CYP2D6. So the drug is designed for CYP2D6 extensive metabolizers (most patients) where the inhibition boost brings dextromethorphan to therapeutic levels.

CYP2D6 poor metabolizers (about 7 percent of Whites, 3 percent of Asians, 1 to 3 percent of African Americans) already clear dextromethorphan slowly. Adding bupropion inhibition raises levels further. In practice, poor metabolizers get more side effects (dizziness, sedation, GI) at standard doses and may need a lower dose or a different drug. The label mentions this but does not require pretreatment genotyping.

CYP2D6 ultra-rapid metabolizers (a few percent of the population, more common in some Middle Eastern and North African populations) clear dextromethorphan very fast, and the bupropion inhibition may not compensate. Antidepressant response may be blunted. Again, genotyping is not required, but when a patient fails Auvelity for reasons that look like non-response rather than intolerability, CYP2D6 genotype is worth asking about.

Other CYP2D6 inhibitors on board (fluoxetine, paroxetine, other bupropion, duloxetine, quinidine) add to the effect and worsen side effects. Combinations are not absolutely contraindicated but often argue for a different antidepressant.

Drug interactions and contraindications

The absolute contraindications on the label:

• MAOI use within 14 days (serotonin syndrome and hypertensive crisis risk, both from bupropion and from dextromethorphan)
• Seizure disorder (bupropion lowers seizure threshold)
• Anorexia nervosa or bulimia nervosa in the current or prior history (bupropion label class effect)
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs (seizure risk)

Serotonin syndrome risk is real and is worth being explicit about. Dextromethorphan is serotonergic through weak SERT reuptake inhibition and through 5-HT2A activity. Combining Auvelity with SSRIs, SNRIs, triptans, tramadol, linezolid, and any MAOI raises the theoretical risk. Real-world case reports have been uncommon but not zero. In practice, cross-tapers from an SSRI to Auvelity are done cautiously with symptom monitoring.

Bupropion also carries seizure risk that scales with dose. Auvelity's bupropion dose is 210 mg twice daily maximum, which is below the 450 mg per day upper limit for immediate-release bupropion but still relevant. Any medication that lowers the seizure threshold (tramadol, clozapine, certain antibiotics like quinolones, other bupropion products) piles onto that risk.

Other clinically relevant interactions:

• Alcohol raises bupropion-related seizure risk and adds to dizziness. Recommend limiting or avoiding.
• Tobacco cessation may reduce CYP1A2 activity and affect bupropion levels indirectly.
• QT-prolonging drugs plus dextromethorphan: dextromethorphan itself is not a major QT drug, but combinations with other serotonergic agents that prolong QT (some SSRIs at high dose, methadone) need thoughtful review.

Where Auvelity fits right now

Three clear roles in mid-2026:

The first is patients with moderate to severe MDD who need faster relief than SSRIs typically deliver. The evidence for faster onset is not head-to-head against SSRIs, but the week-one separation in GEMINI is real. For a patient with active suicidal ideation being managed outpatient, or a patient with severe anhedonia disrupting work and relationships, an antidepressant that may work in one to two weeks is worth trying even at higher cost.

The second is patients who've had partial response to SSRIs or SNRIs and want a different mechanism. Auvelity's NMDA modulation is a genuine mechanistic shift, similar in family to ketamine and esketamine but oral and outpatient. Some patients respond after failing multiple monoamine-based drugs.

The third is patients who want a ketamine-like mechanism without ketamine's cost, DEA schedule, monitored infusion requirement, or dissociation profile. Auvelity is not ketamine. The effect size is smaller, the onset is slower (day 7 versus day 1 for IV ketamine), and it's not indicated for treatment-resistant depression specifically. But for a patient interested in NMDA modulation as a mechanism and not eligible for or interested in ketamine clinics, Auvelity is the accessible oral option.

What Auvelity is not: first-line for every MDD patient (generic sertraline is cheaper, longer-established, and works for most patients), a substitute for ketamine or esketamine in true treatment-resistant depression (the trials didn't include TRD patients), or a benign choice for anyone with seizure risk or an eating disorder history.

Cost and access

List price is around $675 for a 30-day supply, meaningfully higher than generic bupropion or generic SSRIs. Insurance coverage varies. Commercial coverage often requires prior authorization with documented failure of at least one SSRI/SNRI trial. Medicare Part D has picked it up on most formularies. Medicaid is state-by-state. The manufacturer (Axsome) offers a copay assistance program for commercially insured patients bringing out-of-pocket to under $10 for eligible patients.

The PA documentation that helps: prior trial and either failure or intolerability of at least one SSRI or SNRI at adequate dose for adequate duration, current MADRS or PHQ-9 score documenting moderate to severe depression, and rationale for Auvelity specifically (partial response to monoamine mechanism, patient preference for faster-acting agent, or contraindication to alternative options).

Common questions

How does Auvelity compare to ketamine or esketamine? Same broad NMDA-modulating family. Ketamine and esketamine act faster (24 to 48 hours) and have larger effect sizes in TRD populations, but they require monitored administration, DEA scheduling handling, and are limited to specific clinic settings. Auvelity is oral, outpatient, and easier to prescribe but slower in onset and smaller in effect. For truly treatment-resistant depression, ketamine or esketamine remain more evidence-based. For general MDD with a partial response to SSRIs, Auvelity is a reasonable oral alternative.

Can Auvelity be combined with an SSRI? Not usually recommended. Both drugs are serotonergic (Auvelity through dextromethorphan, SSRIs directly). Combinations have been done in practice as short-term cross-tapers, but sustained combination raises serotonin syndrome risk and doubles the pill burden without clear efficacy justification. A cross-taper from SSRI to Auvelity is standard when switching.

What if a patient is on bupropion already? Adding Auvelity to a patient already on bupropion (Wellbutrin or generic) means double-dosing the bupropion component. That is a seizure risk problem. If a patient has done well on bupropion and is switching to Auvelity for augmentation or better response, cross-taper the bupropion off first (over 1 to 2 weeks) before starting Auvelity.

Does Auvelity cause sexual side effects? Less than SSRIs and SNRIs in the trial data. The bupropion component is known to be sexually neutral or beneficial. Dextromethorphan is not typically associated with sexual dysfunction. Practical implication: for a patient discontinuing an SSRI because of sexual side effects, Auvelity is a reasonable next step and often preserves or improves sexual function.

What about weight? Trial data showed no significant weight gain over the 6-week trial period. Longer-term real-world experience suggests either weight neutrality or modest weight loss, similar to bupropion monotherapy. This matters for patients discontinuing SSRIs or SNRIs specifically because of weight gain.

Can Auvelity be used in bipolar depression? The trials excluded bipolar patients. The bupropion component carries theoretical mania induction risk, similar to any antidepressant used in bipolar disorder without mood stabilization. Off-label use in bipolar depression should be paired with a mood stabilizer at minimum, and this is not what the label supports. For bipolar depression specifically, lurasidone, quetiapine, cariprazine, and lumateperone have direct indications and are the more evidence-based choices.

Is Auvelity a controlled substance? No. Dextromethorphan at Auvelity's dose is not scheduled, and bupropion is not scheduled. That contrasts with esketamine (Schedule III) and ketamine (Schedule III), which are both federally controlled. The unscheduled status is one of Auvelity's real practical advantages for outpatient use.

How is Auvelity discontinued? No specific taper is required by the label. Discontinuation without taper is generally tolerated, though some patients report brief dizziness, GI symptoms, or mood dip similar to SSRI discontinuation. For a patient stopping Auvelity after a full response, a slow taper over 1 to 2 weeks by dropping to once-daily dosing before stopping is reasonable practice, though not strictly required.

Does Auvelity work for anxiety? The trials focused on depression. Anxiety symptoms improved along with depressive symptoms in GEMINI, similar to what SSRIs show. There's no dedicated anxiety indication and no compelling anxiety-specific trial. For pure generalized anxiety or panic disorder, SSRIs, SNRIs, and buspirone remain first-line.

What's next

Axsome has run and reported an extension trial, MERIDIAN, in patients who continued Auvelity for 12 months. The safety and durability signals are broadly reassuring: no unexpected long-term adverse events, and response is maintained in most patients who initially responded. That's what a real MDD drug needs to show.

The next question for the field is whether NMDA-modulating antidepressants become a genuine second-line class alongside SSRIs, SNRIs, and atypicals. Auvelity is one drug in what may become a family. Other NMDA modulators are in development, and if the class produces two or three effective, tolerable oral drugs, the antidepressant paradigm shifts.

The other question is real-world durability. Six-week trials show fast response. Twelve-month extension data shows continued response. What happens at 24 or 36 months is not yet characterized, and antidepressant relapse rates over multi-year follow-up are what shape long-term treatment planning.

Sources

• Tabuteau H, Jones A, Anderson A, et al. Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022;179(7):490-499. (ASCEND)
• Iosifescu DV, Jones A, O'Gorman C, et al. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in adults with major depressive disorder: GEMINI. Am J Psychiatry. 2022;179(7):457-467.
• Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets. Prescribing information. Axsome Therapeutics; approved August 18, 2022. Available via DailyMed.
• Anderson A, Jones A, Streicher C, et al. AXS-05 in the treatment of depression: long-term efficacy and safety (MERIDIAN). Presented at American Society of Clinical Psychopharmacology, 2024.
• Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and antidepressants (relevant for polymorphism interpretation).